Current Report · Items 3.03, 5.03, 8.01, 9.01 · 8-K
Allurion Technologies, Inc.
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Other Events
Item 3.03 Material Modification to Rights of Security Holders. To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.
Filed Jun 17, 2026Accepted Jun 17, 2026, 4:35 PM EDTCIK 1964979Accession 0001193125-26-274250
Company context
Allurion is a pioneer in metabolically healthy weight loss. The Allurion Program is a weight-loss platform that combines the Allurion Smart Capsule, the world’s first and only swallowable, ProcedurelessTM gastric balloon for weight loss, the Allurion Virtual Care Suite, including the Allurion Mobile App for consumers and Allurion Insights for healthcare providers featuring the Iris AI Platform, and the Allurion Connected Scale. The Allurion Virtual Care Suite is also available to providers separately from the Allurion Program to help customize, monitor, and manage weight-loss therapy for patients regardless of their treatment plan. The Allurion Smart Capsule is an investigational device in the United States.
Current securities
Historical securities (4)
Registered securities in this filing
Allurion Technologies, Inc. · 8-K · Filed 2026-06-17
As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.
Common stock, par value $0.0001 per share
- Symbol
- ALUR
- Exchange
- NONE
- Classification
- COMMON
Filing context
Context: C_bee770f8-8bb9-474e-a165-7baceac3e3cb
Dimensions: us-gaap:StatementClassOfStockAxis
Warrants to purchase 0.056818 shares of common stock, each at an exercise price of $202.50 per share of common stock
- Symbol
- ALUR WS
- Exchange
- NONE
- Classification
- WARRANT
Filing context
Context: C_4d122b15-d6e8-412c-99af-ae8c7c69f417
Dimensions: us-gaap:StatementClassOfStockAxis
Accession 000119312526274250 · 2 registered-security cover members
Read the exact SEC filing ↗Disclosure sections
Items 3.03, 5.03, 8.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 3.03Item 3.03 - Material Modification to Rights
Item 3.03 Material Modification to Rights of Security Holders.
To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K is incorporated by reference herein.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
As previously disclosed, at the 2025 Annual Meeting of Stockholders of Allurion Technologies, Inc. (the “Company”) held on December 18, 2025 (the “Annual Meeting”), and upon the recommendation of the Board of Directors (the “Board”) of the Company, the Company’s stockholders approved a certificate of amendment (the “Charter Amendment”) to the Company’s Amended and Restated Certificate of Incorporation, as amended to date (the “Certificate of Incorporation”), to effect a reverse stock split of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a ratio between 1-for-1.5 and 1-for-20, with the final ratio to be determined by the Board in its sole discretion.
Following the Annual Meeting, the Pricing Committee of the Board approved a reverse stock split of the Common Stock at a ratio of 1-for-15 (the “Reverse Stock Split”) and on June 12, 2026, the Company filed an amendment, as amended by a Certificate of Correction thereto (the “Certificate of Amendment”), to its Certificate of Incorporation to effectuate the Reverse Stock Split. FINRA processed and announced the Reverse Stock Split on June 17, 2026, which shall take effect on the OTCQB Market (the “Market”) on June 18, 2026.
As a result of the Reverse Stock Split, every 15 shares of the Company’s Common Stock issued or outstanding will be automatically reclassified into one validly issued, fully-paid and non-assessable new share of Common Stock, subject to the treatment of fractional shares as described below, without any action on the part of the holders. Trading of the Common Stock on the Market will commence on a split-adjusted basis at market open on June 18, 2026, under the temporary trading symbol “ALURD” for a period of twenty (20) days. After twenty (20) business days, the trading symbol will revert back to “ALUR.” The new CUSIP number for the Company’s Common Stock following the Reverse Stock Split will be 02008G 300.
No fractional shares will be issued in connection with the Reverse Stock Split. Stockholders who would otherwise be entitled to receive fractional shares as a result of the Reverse Stock Split will automatically be entitled to receive an additional fraction of a share of Common Stock to round up to the next whole share.
Proportional adjustments will also be made to the number of shares of Common Stock awarded and available for issuance under the Company’s equity incentive plans, as well as the exercise price and the number of shares issuable upon the exercise or conversion of the Company’s outstanding stock options, restricted stock units and other equity securities under the Company’s equity incentive plans. Additionally, all outstanding convertible notes will be adjusted in accordance with their terms, which will, among other changes to the convertible note terms, result in proportionate adjustments being made to the number of shares issuable upon exercise of such convertible notes and to the exercise and redemption prices of such convertible notes. All outstanding warrants will also be adjusted in accordance with their terms, which will, among other changes to the warrant terms, result in proportionate adjustments being made to the number of shares issuable upon exercise of such warrants and to the exercise and redemption prices of such warrants. Specifically with respect to the Company’s public warrants, following the effectiveness of the reverse stock split, every fifteen (15) shares of Common Stock that may be purchased pursuant to the exercise of public warrants will represent one share of Common Stock that may be purchased pursuant to such warrants. Accordingly, for the Company’s warrants trading under the symbol “ALUR WS” on the Market, each whole public warrant will be exercisable for 0.00378787 shares of common stock at an exercise price of $3,037.50 per share of Common Stock, which is based on each public warrant being exercisable for 0.056818 shares of common stock before the reverse stock split, adjusted for the 15-to-1 reverse stock split ratio.
The foregoing description of the Charter Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Charter Amendment, a copy of which is filed as Exhibit 3.1 to this Form 8-K and is incorporated herein by reference.
Item 8.01Item 8.01 - Other Events
Item 8.01 Other Events.
On June 17, 2026, the Company issued a press release announcing the Reverse Stock Split and other related information. A copy of the press release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Cautionary Note Regarding Forward Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. federal and state securities laws. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions and include statements regarding the effectiveness of the Reverse Stock Split and the effects of
the Reverse Stock Split, including the trading of the Company’s common stock and public warrants on the Market following the Reverse Stock Split. Forward-looking statements are predictions, projections and other statements about future events that reflect the current beliefs and assumptions of the Company’s management based on information currently available to them and, as a result, are subject to risks and uncertainties. Many factors could cause actual future results or developments to differ materially from the forward-looking statements in this communication, including but not limited to (i) the ability of the Company to maintain regulatory approvals for and successfully commercialize its products and offerings, including the Allurion Balloon, (ii) the timing of, and results from, the Company’s clinical studies and trials, (iii) the evolution of the markets in which the Company competes, (iv) the ability of the Company to defend its intellectual property and satisfy regulatory requirements, (v) the impact of global economic conditions and geopolitical events on the Company’s business, (vi) the Company’s expectations regarding its market opportunities, (vii) the risk of economic downturns and a changing regulatory landscape in the highly competitive industry in which the Company operates, (viii) the risk that the Company’s noncompliance with New York Stock Exchange (“NYSE”) continued listing standards may impact the Company’s results of operations, business operations and reputation and the trading prices and volatility of the Company’s common stock, (ix) the Company’s ability to regain compliance with NYSE continued listing standards or to satisfy the initial listing standards of another nationally recognized securities exchange and (x) the Company’s ability to complete a transaction or transactions on acceptable terms, or at all, to achieve compliance with NYSE continued listing standards or the initial listing standards of another nationally recognized securities exchange. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s Annual Report on Form 10-K filed on March 30, 2026 and other documents filed by the Company from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. The Company undertakes no obligation to update any forward-looking statements to reflect any new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events, other than as required by applicable law.
Filed exhibits (1)
EX-99.1 (by filename) alur-ex99_1.htmEX-99.1
3
alur-ex99_1.htm
EX-99.1
EX-99.1
Exhibit 99.1
Allurion Advances Plan to Re-List
NATICK, Mass. - June 17, 2026 - Allurion Technologies, Inc. (OTCQB: ALUR), a pioneer in metabolically healthy weight loss, today announced a 1-for-15 reverse stock of its outstanding common stock intended to support regaining compliance with the continued listing requirements of the New York Stock Exchange (the “NYSE”) or initial listing requirements of the NYSE American.
Allurion continues to actively engage with national exchanges and is advancing its re-listing strategy as part of a comprehensive plan to strengthen its capital markets positioning.
“We have had a constructive and collaborative dialogue with the national exchanges throughout this process, and we remain focused on meeting all requirements necessary to regain our listing,” said Dr. Shantanu Gaur, Founder & CEO of Allurion. “We believe re-listing will enhance our visibility, improve liquidity for our shareholders, and better position Allurion for long-term growth as we continue to execute on our U.S. commercial strategy.”
The reverse stock split will take effect at 12:01 a.m. Eastern Time on June 18, 2026, and the Compa…
Open exhibit ↗